Donation

The IMF’s Understanding series of cancer information booklets is designed to acquaint you with specific multiple myeloma-related tests, treatments and therapies, supportive care measures, and common adverse events.

 

Patient Handbook for Multiple Myeloma
April 23, 2025

Understanding a complex disease like myeloma can feel like you must learn a new language very quickly. The IMF’s signature publication, …

Order Print
Order Digital
Request a Free IMF Info Pack
August 01, 2023

Full of our informative publications, including our Patient Handbook and selections from the popular Understanding Series, the Info Pack will…

Order Print
Understanding ABECMA® (idecabtagene vicleucel)
July 01, 2024
Immunotherapy with Abecma® (idecabtagene vicleucel or “ide-cel” for short) is FDA-approved for the treatment of relapsed refractory multiple myeloma…
Order Print
Order Digital
Understanding Carvykti®
March 17, 2025

Carvykti® (ciltacabtagene autoleucel, or “cilta-cel” for short) is a customized immunotherapy approved by the FDA for the treatment of patients…

Order Print
Order Digital
Understanding CELMoDs (Cereblon E3 Ligase Modulatory Drugs)
September 02, 2024
This booklet serves as an introduction to cereblon E3 ligase modulatory drugs (CELMoDs), a new class of medications currently being studied in…
Order Digital
Order Print
Understanding Clinical Trials in Myeloma
November 20, 2024
This publication discusses what myeloma patients should consider if enrolling in a clinical trial.
Order Print
Order Digital
Understanding DARZALEX and DARZALEX FASPRO
January 28, 2025

Darzalex® (daratumumab) is the first monoclonal antibody approved by the FDA that targets the CD38 protein on the surface of myeloma cells,…

Order Print
Order Digital
Understanding Dexamethasone
October 14, 2024
This booklet discusses dexamethasone, a synthetic steroid that is one of the most frequently used medica­tions in the treatment of myeloma.
Order Print
Order Digital
Understanding Elrexfio
March 13, 2025
Elrexfio™ (elranatamab-bcmm) is a B-cell maturation antigen (BCMA)-directed CD3 T-cell engager.
Order Print
Order Digital
Understanding EMPLICITI®
January 24, 2025

Empliciti® (elotuzumab) is the first immunostimulatory monoclonal antibody approved for the treatment of myeloma. Empliciti enlists immune system…

Order Print
Order Digital
Understanding Fatigue
December 05, 2024
Patients with myeloma may experience fatigue caused by the disease itself or by treatment for myeloma, as well as by other medical problems or their…
Order Print
Order Digital
Understanding KYPROLIS® (carfilzomib) for Injection
July 01, 2024
This publication discusses the use of Kyprolis (carfilzomib)— a proteasome inhibitor—for the treatment of myeloma.
Order Print
Order Digital
Understanding MGUS and Smoldering Myeloma
February 21, 2025
This publication covers monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
Order Print
Order Digital
Understanding Myeloma Vocabulary
September 02, 2024
The International Myeloma Foundation provides this glossary that defines commonly used multiple myeloma-related terms
Order Print
Order Digital
Understanding Neuropathy in Myeloma
March 05, 2025
This publication discusses peripheral neuropathy, which can be a complication of multiple myeloma or its treatments.
Order Print
Order Digital
Understanding NINLARO®
March 01, 2024
This publication discusses the use of Ninlaro (ixazomib)—a proteasome inhibitor—for the treatment of myeloma.
Order Print
Order Digital
Understanding Pomalyst® (pomalidomide) capsules
March 08, 2024
This publication discusses the use of Pomalyst (pomalidomide)—an immunomodulatory drug (IMiD)—for the treatment of myeloma.
Order Print
Order Digital
Understanding Revlimid® (lenalidomide)
November 28, 2024
This publication discusses the use of Revlimid (lenalidomide)—an immunomodulatory drug (IMiD)—for the treatment of myeloma.
Order Print
Order Digital
Understanding SARCLISA®
January 23, 2025
The Understanding SARCLISA® (isatuximab-irfc) booklet discusses a novel anti-CD38 monoclonal antibody that is approved for patients with relapsed and…
Order Print
Order Digital
Understanding Stem Cell Transplant in Myeloma
November 19, 2024
This publication is for myeloma patients in the U.S. who are considering undergoing an autologous stem cell transplant (ASCT).
Order Print
Order Digital
Understanding TALVEY™
November 15, 2023
Talvey is indicated for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least 4 prior lines of therapy.
Order Print
Order Digital
Understanding Tecvayli
February 26, 2024
Tecvayli™ (teclistamab-cqyv) is the first in a drug class of bispecific antibodies approved by the FDA to treat myeloma.
Order Print
Order Digital
Understanding Thalidomide Therapy
May 16, 2024
This publication discusses the use of Thalomid (Thalidomide)—an immunomodulatory drug (IMiD)—for the treatment of myeloma.
Order Print
Order Digital
Understanding the Immune System in Myeloma
September 02, 2024
This publication discusses the effects of multiple myeloma on the immune system.
Order Print
Order Digital
Understanding the VRd Regimen for Newly Diagnosed Myeloma
January 28, 2025
This booklet discusses Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone as treatment for newly diagnosed myeloma.
Order Print
Order Digital
Understanding Treatment of Myeloma Bone Disease
February 11, 2025
This publication focuses on therapies (such as bisphosphonates) given to patient with myeloma bone lesions, lytic lesions, or myeloma bone disease.
Order Print
Order Digital
Understanding Treatment of Myeloma-Induced Vertebral Compression Fractures
May 18, 2019
This publication discusses how myeloma patients can manage vertebral compression fractures.
Order Print
Order Digital
Understanding Velcade (bortezomib) for Injection
March 05, 2025
This publication discusses the use of Velcade (bortezomib)—a proteasome inhibitor—for the treatment of myeloma.
Order Print
Order Digital
Understanding Xpovio (selinexor)
May 17, 2021
This booklet discusses Xpovio (selinexor) for the treatment of multiple myeloma.
Order Print
Order Digital
Understanding Your Test Results
March 06, 2025
This booklet outlines the various tests that are used to diagnose and monitor myeloma, and to detect response and relapse.
Order Print
Order Digital

with support from:

Johnson & Johnson, Sanofi, and Pfizer.

Give Where Most Needed

Learn More